Literature DB >> 19789362

Transport of the photodynamic therapy agent 5-aminolevulinic acid by distinct H+-coupled nutrient carriers coexpressed in the small intestine.

Catriona M H Anderson1, Mark Jevons, Muthusamy Thangaraju, Noel Edwards, Nichola J Conlon, Steven Woods, Vadivel Ganapathy, David T Thwaites.   

Abstract

5-Aminolevulinic acid (ALA) is a prodrug used in photodynamic therapy, fluorescent diagnosis, and fluorescent-guided resection because it leads to accumulation of the photosensitizer protoporphyrin IX (PpIX) in tumor tissues. ALA has good oral bioavailability, but high oral doses are required to obtain selective PpIX accumulation in colonic tumors because accumulation is also observed in normal gut mucosa. Structural similarities between ALA and GABA led us to test the hypothesis that the H(+)-coupled amino acid transporter PAT1 (SLC36A1) will contribute to luminal ALA uptake. Radiolabel uptake and electrophysiological measurements identified PAT1-mediated H(+)-coupled ALA symport after heterologous expression in Xenopus oocytes. The selectivity of the nontransported inhibitors 5-hydroxytryptophan and 4-aminomethylbenzoic acid for, respectively, PAT1 and the H(+)-coupled di/tripeptide transporter PepT1 (SLC15A1) were examined. 5-Hydroxytryptophan selectively inhibited PAT1-mediated amino acid uptake across the brush-border membrane of the human intestinal (Caco-2) epithelium whereas 4-aminomethylbenzoic acid selectively inhibited PepT1-mediated dipeptide uptake. The inhibitory effects of 5-hydroxytryptophan and 4-aminomethylbenzoic acid were additive, demonstrating that both PAT1 and PepT1 contribute to intestinal transport of ALA. This is the first demonstration of overlap in substrate specificity between these distinct transporters for amino acids and dipeptides. PAT1 and PepT1 expression was monitored by reverse transcriptase-polymerase chain reaction using paired samples of normal and cancer tissue from human colon. mRNA for both transporters was detected. PepT1 mRNA was increased 2.3-fold in cancer tissues. Thus, increased PepT1 expression in colonic cancer could contribute to the increased PpIX accumulation observed. Selective inhibition of PAT1 could enhance PpIX loading in tumor tissue relative to that in normal tissue.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19789362      PMCID: PMC2802479          DOI: 10.1124/jpet.109.159822

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  40 in total

1.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.

Authors:  Walter Stummer; Uwe Pichlmeier; Thomas Meinel; Otmar Dieter Wiestler; Friedhelm Zanella; Hans-Jürgen Reulen
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

2.  Vigabatrin transport across the human intestinal epithelial (Caco-2) brush-border membrane is via the H+ -coupled amino-acid transporter hPAT1.

Authors:  Emily L Abbot; Danielle S Grenade; David J Kennedy; Kelly M Gatfield; David T Thwaites
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

3.  Recognition and transport characteristics of nonpeptidic compounds by basolateral peptide transporter in Caco-2 cells.

Authors:  M Irie; T Terada; K Sawada; H Saito; K Inui
Journal:  J Pharmacol Exp Ther       Date:  2001-08       Impact factor: 4.030

4.  Substrate specificity of the amino acid transporter PAT1.

Authors:  L Metzner; K Neubert; M Brandsch
Journal:  Amino Acids       Date:  2006-05-15       Impact factor: 3.520

5.  Serotonin, L-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1.

Authors:  Linda Metzner; Gabor Kottra; Klaus Neubert; Hannelore Daniel; Matthias Brandsch
Journal:  FASEB J       Date:  2005-09       Impact factor: 5.191

Review 6.  Deciphering the mechanisms of intestinal imino (and amino) acid transport: the redemption of SLC36A1.

Authors:  David T Thwaites; Catriona M H Anderson
Journal:  Biochim Biophys Acta       Date:  2006-10-07

7.  4-aminomethylbenzoic acid is a non-translocated competitive inhibitor of the epithelial peptide transporter PepT1.

Authors:  D Meredith; C A Boyd; J R Bronk; P D Bailey; K M Morgan; I D Collier; C S Temple
Journal:  J Physiol       Date:  1998-11-01       Impact factor: 5.182

8.  Peptide transporter 2 (PEPT2) expression in brain protects against 5-aminolevulinic acid neurotoxicity.

Authors:  Yongjun Hu; Hong Shen; Richard F Keep; David E Smith
Journal:  J Neurochem       Date:  2007-09-13       Impact factor: 5.372

9.  Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer.

Authors:  Naren Gupta; Pamela M Martin; Seiji Miyauchi; Sudha Ananth; Anne V Herdman; Robert G Martindale; Robert Podolsky; Vadivel Ganapathy
Journal:  Biochem Biophys Res Commun       Date:  2006-03-09       Impact factor: 3.575

Review 10.  H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine.

Authors:  David T Thwaites; Catriona M H Anderson
Journal:  Exp Physiol       Date:  2007-04-27       Impact factor: 2.969

View more
  16 in total

1.  Ibuprofen is a non-competitive inhibitor of the peptide transporter hPEPT1 (SLC15A1): possible interactions between hPEPT1 substrates and ibuprofen.

Authors:  Diana Højmark Omkvist; Birger Brodin; Carsten Uhd Nielsen
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

2.  SLC36A4 (hPAT4) is a high affinity amino acid transporter when expressed in Xenopus laevis oocytes.

Authors:  Samyuktha Muralidharan Pillai; David Meredith
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

Review 3.  The SLC36 family of proton-coupled amino acid transporters and their potential role in drug transport.

Authors:  David T Thwaites; Catriona M H Anderson
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

Review 4.  Function, Regulation, and Pathophysiological Relevance of the POT Superfamily, Specifically PepT1 in Inflammatory Bowel Disease.

Authors:  Emilie Viennois; Adani Pujada; Jane Zen; Didier Merlin
Journal:  Compr Physiol       Date:  2018-03-25       Impact factor: 9.090

5.  The proton-coupled amino acid transporter, SLC36A1 (hPAT1), transports Gly-Gly, Gly-Sar and other Gly-Gly mimetics.

Authors:  S Frølund; R Holm; B Brodin; C U Nielsen
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

6.  Delta-aminolevulinic acid is a substrate for the amino acid transporter SLC36A1 (hPAT1).

Authors:  S Frølund; O C Marquez; M Larsen; B Brodin; C U Nielsen
Journal:  Br J Pharmacol       Date:  2010-01-27       Impact factor: 8.739

Review 7.  Key transporters leading to specific protoporphyrin IX accumulation in cancer cell following administration of aminolevulinic acid in photodynamic therapy/diagnosis.

Authors:  Hung Wei Lai; Taku Nakayama; Shun-Ichiro Ogura
Journal:  Int J Clin Oncol       Date:  2020-09-01       Impact factor: 3.402

8.  The proton-coupled oligopeptide transporter 1 plays a major role in the intestinal permeability and absorption of 5-aminolevulinic acid.

Authors:  Yehua Xie; Yongjun Hu; David E Smith
Journal:  Br J Pharmacol       Date:  2015-11-25       Impact factor: 8.739

Review 9.  Intracellular amino acid sensing and mTORC1-regulated growth: new ways to block an old target?

Authors:  Deborah C I Goberdhan
Journal:  Curr Opin Investig Drugs       Date:  2010-12

Review 10.  The human proton-coupled folate transporter: Biology and therapeutic applications to cancer.

Authors:  Sita Kugel Desmoulin; Zhanjun Hou; Aleem Gangjee; Larry H Matherly
Journal:  Cancer Biol Ther       Date:  2012-09-06       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.